RU2007146986A - Способы лечения опухолей головного мозга с использованием антител - Google Patents

Способы лечения опухолей головного мозга с использованием антител Download PDF

Info

Publication number
RU2007146986A
RU2007146986A RU2007146986/14A RU2007146986A RU2007146986A RU 2007146986 A RU2007146986 A RU 2007146986A RU 2007146986/14 A RU2007146986/14 A RU 2007146986/14A RU 2007146986 A RU2007146986 A RU 2007146986A RU 2007146986 A RU2007146986 A RU 2007146986A
Authority
RU
Russia
Prior art keywords
mab
growth factor
nrg
brain tumor
fgf
Prior art date
Application number
RU2007146986/14A
Other languages
English (en)
Russian (ru)
Inventor
Киунг Дэин КИМ (US)
Киунг Дэин КИМ
Джон ЛАТЕРРА (US)
Джон ЛАТЕРРА
Баччу ЛАЛ (US)
Баччу ЛАЛ
Original Assignee
ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US)
ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи
Кеннеди Кригер Инститьют, Инк. (Us)
Кеннеди Кригер Инститьют, Инк.
Джонс Хопкинс Юниверсити (Us)
Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US), ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи, Кеннеди Кригер Инститьют, Инк. (Us), Кеннеди Кригер Инститьют, Инк., Джонс Хопкинс Юниверсити (Us), Джонс Хопкинс Юниверсити filed Critical ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US)
Publication of RU2007146986A publication Critical patent/RU2007146986A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2007146986/14A 2005-06-02 2006-06-01 Способы лечения опухолей головного мозга с использованием антител RU2007146986A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68711805P 2005-06-02 2005-06-02
US60/687,118 2005-06-02
US75109205P 2005-12-15 2005-12-15
US60/751,092 2005-12-15

Publications (1)

Publication Number Publication Date
RU2007146986A true RU2007146986A (ru) 2009-06-27

Family

ID=37482322

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007146986/14A RU2007146986A (ru) 2005-06-02 2006-06-01 Способы лечения опухолей головного мозга с использованием антител

Country Status (14)

Country Link
US (2) US20070036797A1 (https=)
EP (1) EP1885400A4 (https=)
JP (2) JP2008545753A (https=)
KR (1) KR20080026562A (https=)
AU (1) AU2006252419B2 (https=)
BR (1) BRPI0611009A2 (https=)
CA (1) CA2607699A1 (https=)
CR (1) CR9512A (https=)
IL (1) IL187318A0 (https=)
MA (1) MA29570B1 (https=)
MX (1) MX2007015056A (https=)
NO (1) NO20080012L (https=)
RU (1) RU2007146986A (https=)
WO (1) WO2006130773A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2439160C1 (ru) * 2010-06-25 2012-01-10 Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AR061171A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch)
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
KR20090088946A (ko) * 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
WO2009027332A1 (en) * 2007-08-24 2009-03-05 Novartis Ag A modulator of nrg1 for treatment of respiratory disorders
TW200948380A (en) * 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
JP5972573B2 (ja) * 2008-05-29 2016-08-17 ギャラクシー バイオテック， エルエルシー 塩基性線維芽細胞成長因子に対するモノクローナル抗体
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
DK2536748T3 (da) * 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
US20130315895A1 (en) * 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
IL127558A0 (en) * 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
KR101254371B1 (ko) * 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
PT2213661E (pt) * 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
WO2007056523A2 (en) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CL2009000843A1 (es) * 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2439160C1 (ru) * 2010-06-25 2012-01-10 Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов

Also Published As

Publication number Publication date
CA2607699A1 (en) 2006-12-07
JP2013136580A (ja) 2013-07-11
IL187318A0 (en) 2008-04-13
BRPI0611009A2 (pt) 2010-08-10
MA29570B1 (fr) 2008-06-02
CR9512A (es) 2008-04-16
US20070036797A1 (en) 2007-02-15
NO20080012L (no) 2008-02-20
EP1885400A4 (en) 2011-01-26
JP2008545753A (ja) 2008-12-18
AU2006252419A1 (en) 2006-12-07
EP1885400A2 (en) 2008-02-13
WO2006130773A2 (en) 2006-12-07
KR20080026562A (ko) 2008-03-25
MX2007015056A (es) 2008-03-11
WO2006130773A3 (en) 2009-04-16
AU2006252419B2 (en) 2012-02-02
US20100221250A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
RU2007146986A (ru) Способы лечения опухолей головного мозга с использованием антител
JP2008545753A5 (https=)
Pasquier et al. Angiocrine endothelium: from physiology to cancer
Kazanis et al. Alterations in IGF-I, BDNF and NT-3 levels following experimental brain trauma and the effect of IGF-I administration
Lynch et al. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment
Logan et al. Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor‐β2
McAvoy et al. Growth factors in the eye
Ferrara VEGF-A: a critical regulator of blood vessel growth
Krieglstein Factors promoting survival of mesencephalic dopaminergic neurons
WO2007145862B1 (en) Extending survival of cancer patients with elevated levels of egf or tgf-alpha
RU2006140257A (ru) Моноклональные антитела к фактору роста гепатоцитов
US20080241157A1 (en) Nerve cell growth modulators (amphibodies)
Moumdjian et al. Origin of contralateral reactive gliosis in surgically injured rat cerebral cortex
KR20120099751A (ko) 줄기 세포 자극용 약학 조성물
JP2019521156A5 (https=)
RU2012151889A (ru) Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr
McCormick et al. Neural regenerative strategies incorporating biomolecular axon guidance signals
R Quesada et al. Do not say ever never more: the ins and outs of antiangiogenic therapies
WO2023235767A3 (en) Development of a novel therapeutic cd99 antibody to treat aggressive solid tumors in children
US20100130904A1 (en) Method to inhibit proliferation and growth of metastases
Krishnan et al. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas
Han Growth factor therapy
CN103459423B (zh) 结合TGF-α和EPIREGULIN的抗体
Asai et al. Successful treatment of diabetic gangrene with topical application of a mixture of peripheral blood mononuclear cells and basic fibroblast growth factor
Yoshida et al. Neurotrophic activity in cytokine-activated astrocytes

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20101106